Date: 24th September 2021
Twist Bioscience announced yesterday a collaboration with deep learning experts, deepCDR, which will advance antibody discovery and optimisation capabilities.
Twist Bioscience, based in San Francisco, US, is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialise the engineering of biology. They are pioneers of a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. They also have expertise in designing and synthesising very large antibody libraries as well as optimising potential antibodies to improve their biochemical properties.
deepCDR Biologics, based in Basel, Switzerland, is a biotechnology company that provides cutting-edge technologies and services. They use unique deep learning methods combined with their proprietary mammalian display platform to select from a massively wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles.
With Twist’s expertise in large antibody libraries and deepCDRs deep learning technologies generating large panels of fully human antibody sequences, the collaboration has seen fully human naïve synthetic antibody libraries being built – specifically AI Hypermutated single-chain fragment variable (scFv) library and a new coronavirus specific scFv library.
This latest collaboration will hope to accelerate antibody libraries for drug discovery and development. It adds to a new wave of AI-driven healthcare and pharmaceutical collaborations, which has recently seen the likes of Valence Discovery and Repare Therapeutics entering into a drug discovery agreement, leveraging Valence’s unique expertise in machine learning drug design with Repare’s propriety drug discovery using a synthetic lethality approach. Other industry giants such as Boehringer Ingelheim and Google Quantum AI (Google) have entered a collaboration which focuses on researching and implementing cutting-edge use for quantum computing in pharmaceutical research and development (R&D). Novartis and Microsoft are revolutionising the future of drug development by combining advanced AI technology with deep life science expertise.
These digital technologies are transforming our healthcare and pharmaceutical industries. With artificial intelligence, machine and deep learning, giving us a greater depth of understanding of diseases and accelerating a new generation of drugs and therapies.
For more information please see the press release at Business Wire
